Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We have previously demonstrated that the ester conjugation of zidovudine (AZT) with ursodeoxycholic acid (UDCA) allows to obtain a prodrug (U-AZT) which eludes the active efflux transporters (AET). This allows the prodrug to more efficiently permeates and remains in murine macrophages than the parent compound. Here we demonstrate that U-AZT can be formulated, by a nanoprecipitation method, as nanoparticle cores coated by bile acid salt (taurocholate or ursodeoxycholate) corona, without any other excipients. The U-AZT nanoparticles appeared spherical with a mean diameter of ∼200 nm and a zeta potential of ∼-55 mV. During the incubation (5 h) in fetal bovine serum, the ursodeoxycholate-coated nanoparticle size did not change. Differently, taurocholate-coated particle size was firstly reduced and then increased up to 800 µm, thus suggesting the high aptitude of these nanoparticles to interact with serum proteins. The in vitro uptake of taurocholate coated particles by murine macrophages was strongly higher than that of ursodeoxycholate-coated particles or free U-AZT (∼500% and ∼7000%, respectively). AZT was also detected in macrophages following the prodrug uptake, with the greatest amounts observed after the taurocholate-coated nanoparticle incubation. As macrophages in the subarachnoid spaces of cerebrospinal fluid (CSF) constitute one of the most unreachable HIV sanctuaries in the body, we also tested the ability of taurocholate-coated nanoparticles (i.e., nanoparticles highly internalized by macrophages) to reach them after their nasal administration in the presence or absence of chitosan. The results indicate that chitosan allowed to obtain a relatively high uptake (up to 4 µg/ml) of U-AZT in CSF. Taking into account that chitosan may promote the direct brain nanoparticle uptake, these findings can be considered an initial step toward the in vivo targeting of the subarachnoid macrophages by U-AZT prodrug.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2019.09.008DOI Listing

Publication Analysis

Top Keywords

allows prodrug
8
murine macrophages
8
u-azt
6
macrophages
6
uptake
5
prodrug
5
bile salt-coating
4
salt-coating modulates
4
modulates macrophage
4
macrophage uptake
4

Similar Publications

Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.

Clin Biochem

September 2025

Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E6, Canada; Department of Pathology and Laboratory Medicine, Saskatchewan Health Authority, Saskatoon, SK S7M 0Z9, Canada. Electronic address:

Background: 5-Fluorouracil (5-FU) and its pro-drug, capecitabine, are widely used to treat solid tumors. Patients with dihydropyrimidine dehydrogenase (DPYD) deficiency are at increased risk for severe treatment-related toxicity. This study reported the implementation of DPYD genotyping in clinical practice and assessed the impact of genotype-guided dosing on clinical outcomes.

View Article and Find Full Text PDF

Targeted protein degradation (TPD) through the ubiquitin-proteasome system is driven by compound-mediated polyubiquitination of a protein-of-interest by an E3 ubiquitin (Ub) ligase. To date, relatively few E3s have been successfully utilized for TPD and the governing principles of functional ternary complex formation between the E3, degrader, and protein target remain elusive. FBXO22 has recently been harnessed by several groups to target different proteins for degradation.

View Article and Find Full Text PDF

Formosulfathiazole: A Structural Revision.

Chempluschem

September 2025

Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Guido Donegani 2, Novara (NO), 28100, Italy.

Formosulfathiazole (FSTz) is a synthetic active pharmaceutical ingredient (API) prepared by condensation of sulfathiazole with formaldehyde. Originally described for the first time in 1948, it is currently used for the treatment of bacterial and protozoal infections in cattle and pets, acting as a prodrug slowly releasing the sulfamidic sulfathiazole and formaldehyde. A systematic analysis of FSTz allowed to revise the originally believed undefined polymeric structure and uncovered the intriguing cyclophane skeleton of a well-defined cyclodimeric condensation product.

View Article and Find Full Text PDF

Chemotherapy represents a conventional method for cancer treatment, but it inevitably has the issues of low clinical efficacy, therapy resistance and severe side effects. In view of the unique characteristics of nanosystems that can deliver drugs in an effective and safe manner, we report photoactivatable nano-liposomes containing a hypoxia-responsive prodrug tirapazamine (TPZ), glucose oxidase (GOx) and indocyanine green (ICG) for photothermal-triggered chemotherapy of subcutaneous metastatic breast cancer. The nano-liposomes (termed IGT@NPs) are fabricated using a thermo-responsive liposome component to enable photoactivatable drug delivery the photothermal effect.

View Article and Find Full Text PDF

We have had a long-standing interest in developing organic prodrugs for controlled delivery of CO for various therapeutic applications. Based on an earlier approach of taking advantage of a cheletropic extrusion reaction of norbornadienone to release CO, a new structural scaffold of CO prodrugs has been designed using an adamantane moiety instead of aryl groups for stabilizing a critical precursor structure, cyclopentadienone. This approach allows for elimination of multiple aromatic groups on the previous scaffolds and offers a handle for installing additional moieties for improving solubility.

View Article and Find Full Text PDF